Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
August 14 2024 - 4:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
SEC FILE NUMBER |
|
|
333-156091 |
|
NOTIFICATION OF LATE FILING |
|
|
|
|
(Check One): |
☐ |
Form 10-K |
☐ |
Form 20-F |
☐ |
Form 11-K |
☒ |
Form 10-Q |
|
☐ |
Form 10-D |
☐ |
Form N-SAR |
☐ |
Form N-CSR |
|
|
|
For Period Ended: June 30, 2024 |
|
|
|
|
☐ |
Transition Report on Form 10-K |
|
☐ |
Transition Report on Form 20-F |
|
☐ |
Transition Report on Form 11-K |
|
☐ |
Transition Report on Form 10-Q |
|
☐ |
Transition Report on Form N-SAR |
|
|
|
|
For the Transition Period Ended: ___________________ |
Read Instructions (on back page) Before Preparing
Form. Please Print or Type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY
THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
If the notification relates to a portion of the filing
checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Full Name of Registrant: |
Alterola Biotech, Inc. |
Former Name if Applicable: |
n/a |
Address of Principal Executive Offices (Street and Number): |
47 Hamilton Square, Birkenhead Merseyside,
United Kingdom CH415AR
|
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)
|
(a) |
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
☒ |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
|
|
(c) |
The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F,
11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The Registrant has been unable, without
unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to
be included in its Quarterly Report on Form 10-Q for the three months ended June 30, 2024 and to timely approve the Quarterly Report
by the signatories thereto. The Registrant expects to file the Quarterly Report on or before June
19, 2024.
PART IV - OTHER INFORMATION
(1) |
Name and telephone number of person to contact in regard to this notification: |
Colin Stott |
|
+44
|
|
151 601
9477 |
Name |
|
Area Code |
|
Telephone Number |
(2) |
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No |
|
|
(3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No |
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Alterola Biotech,
Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: August
14, 2024 |
By: |
/s/
Colin Stott |
|
|
|
Name: Colin Stott
Title: Chief Operating Officer and Director |
|
|
|
|
|
Instruction: The form may be signed by an executive
officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed
or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.
ATTENTION
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE
FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001). |
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Dec 2023 to Dec 2024